Rapamycin Holdings, Inc. Opens Investigational New Animal Drug Application with the FDA Center for Veterinary Medicine

SAN ANTONIO--(BUSINESS WIRE)--Privately-held Rapamycin Holdings, Inc. (RHI), based in San Antonio, has opened an Investigational New Animal Drug (INAD) application for the therapeutic use of the company's eRapa-NP2gTM compound in the treatment of Feline Chronic Gingivostomatitis (FCGS).

FCGS is a debilitating condition that affects the oral cavity in approximately 200,000 domestic cats annually. Symptoms of this disease include reluctance to eat, pain when opening the mouth or swallowing, increased salivation, and vocalization after taking a bite to eat. Medical management and treatment of this condition is often frustrating, with complete full mouth extractions being the only option these cats have for resolution of symptoms.

Early pre-clinical studies completed by RHI show that the use of eRapa-NP2gTM to address FCGS resulted in:

44% Complete Remission
94% >50% Improvement
78% Average improvement
In addition, these studies show that the company's eRapaTM compound induced decreases in gum tissue immune, inflammatory and abnormal vascular conditions.

According to Rapamycin Holdings CEO Randy Goldsmith, "RHI is actively pursuing regulatory approval for the eRapaTM compound to address significant currently untreatable diseases in the companion animal market, like FCGS which is a debilitating and life threatening disease in cats. We have strong pre-clinical evidence that our product is both safe and highly effective at controlling this terrible disease, and we aspire to bring a treatment to market that will improve the lives of pets and their owners and offer hope for long term survival in diseases where currently there is little hope of a positive outcome due to limited treatment options available."

About eRapaTM

Researchers at the University of Texas Health Science Center San Antonio discovered that an improved formulation of the well-known drug, Rapamycin, extended life span and health span in rodents by mitigating the effects of age-related diseases. Rapamycin Holdings, as the exclusive licensee of this technology, is capitalizing on this discovery by developing a novel patent-pending formulation for the treatment of serious unmet medical needs in humans and companion animals.

About Rapamycin Holdings, Inc.

Rapamycin Holdings holds the exclusive licenses for Rapamycin-related research discoveries made at the University of Texas Health Science Center San Antonio. The company is leveraging a platform of Rapamycin-related discoveries applicable to the veterinary and human markets which could have dramatic implications in improving an individual's health span and in fighting age-related medical conditions.

Contacts
Rapamycin Holdings, Inc.
Lisa Owens, 210-601-6647
[email protected]
or
Randy Goldsmith, 210-478-8678
[email protected]

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…